Active ingredientLenacapavirCat. No. P-L032-001CAS 2189684-44-2Family · Pharmaceutical analytical standards
Lenacapavir
The first inhibitor of the HIV-1 capsid, the p24 protein shell that encloses the virus's genome: authorised in 2022 in Europe and the United States for multidrug-resistant HIV, in 2025 it was also approved for prevention, as a long-acting subcutaneous injection. This family brings together the active ingredient.
Did you know?The journal Science named it its 2024 'Breakthrough of the Year', the scientific discovery of the year, for the results achieved in studies on preventing infection.
Go to the active ingredient →Active ingredientLenacapavirCat. No. P-L032-001CAS 2189684-44-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.